CNS Pharmaceuticals Q3 2026 Earnings Date & Estimates

CNS Pharmaceuticals (NASDAQ:CNSP) is a clinical-stage biotechnology company focused on developing treatments for primary and metastatic cancers of the brain and central nervous system. The company’s research is centered on therapies designed to address the challenges of delivering effective medicines across the blood-brain barrier.

Its lead product candidate is berubicin, an anthracycline designed to penetrate the blood-brain barrier and target malignant brain tumors. CNS Pharmaceuticals has primarily investigated berubicin as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer with limited treatment options. The company’s activities have included clinical development and evaluation of berubicin’s safety and efficacy.

CNS Pharmaceuticals is based in Houston, Texas, and serves the global biopharmaceutical market through its drug-development programs and clinical research activities. The company was founded to advance novel therapies for central nervous system cancers and became a publicly traded company in 2020. Its leadership has included John Climaco, who has served as chief executive officer.